St  ||| S:0 E:3 ||| NNP
John ||| S:3 E:7 ||| NNP
's  ||| S:7 E:10 ||| POS
wort  ||| S:10 E:15 ||| NN
( ||| S:15 E:16 ||| -LRB-
Hypericum  ||| S:16 E:26 ||| UH
perforatum ||| S:26 E:36 ||| UH
)  ||| S:36 E:38 ||| -RRB-
in  ||| S:38 E:41 ||| IN
major  ||| S:41 E:47 ||| JJ
depression  ||| S:47 E:58 ||| NN
The  ||| S:58 E:62 ||| DT
herb  ||| S:62 E:67 ||| JJ
St  ||| S:67 E:70 ||| NNP
John ||| S:70 E:74 ||| NNP
's  ||| S:74 E:77 ||| POS
wort  ||| S:77 E:82 ||| NN
( ||| S:82 E:83 ||| -LRB-
Hypericum  ||| S:83 E:93 ||| UH
perforatum ||| S:93 E:103 ||| UH
)  ||| S:103 E:105 ||| -RRB-
has  ||| S:105 E:109 ||| VBZ
been  ||| S:109 E:114 ||| VBN
used  ||| S:114 E:119 ||| VBN
for  ||| S:119 E:123 ||| IN
centuries  ||| S:123 E:133 ||| NNS
to  ||| S:133 E:136 ||| TO
treat  ||| S:136 E:142 ||| VB
a  ||| S:142 E:144 ||| DT
variety  ||| S:144 E:152 ||| NN
of  ||| S:152 E:155 ||| IN
medical  ||| S:155 E:163 ||| JJ
illnesses ||| S:163 E:172 ||| NNS
.  ||| S:172 E:174 ||| .
In  ||| S:174 E:177 ||| IN
certain  ||| S:177 E:185 ||| JJ
areas  ||| S:185 E:191 ||| NNS
of  ||| S:191 E:194 ||| IN
Europe ||| S:194 E:200 ||| NNP
,  ||| S:200 E:202 ||| ,
St  ||| S:202 E:205 ||| NNP
John ||| S:205 E:209 ||| NNP
's  ||| S:209 E:212 ||| POS
wort  ||| S:212 E:217 ||| NN
has  ||| S:217 E:221 ||| VBZ
been  ||| S:221 E:226 ||| VBN
a  ||| S:226 E:228 ||| DT
commonly  ||| S:228 E:237 ||| RB
prescribed  ||| S:237 E:248 ||| VBN
treatment  ||| S:248 E:258 ||| NN
for  ||| S:258 E:262 ||| IN
depression ||| S:262 E:272 ||| NN
,  ||| S:272 E:274 ||| ,
but ||| S:274 E:277 ||| CC
,  ||| S:277 E:279 ||| ,
in  ||| S:279 E:282 ||| IN
the  ||| S:282 E:286 ||| DT
United  ||| S:286 E:293 ||| NNP
States ||| S:293 E:299 ||| NNPS
,  ||| S:299 E:301 ||| ,
it  ||| S:301 E:304 ||| PRP
is  ||| S:304 E:307 ||| VBZ
available  ||| S:307 E:317 ||| JJ
for  ||| S:317 E:321 ||| IN
purchase  ||| S:321 E:330 ||| NN
over  ||| S:330 E:335 ||| IN
the  ||| S:335 E:339 ||| DT
counter  ||| S:339 E:347 ||| NN
as  ||| S:347 E:350 ||| IN
an  ||| S:350 E:353 ||| DT
herbal  ||| S:353 E:360 ||| JJ
supplement ||| S:360 E:370 ||| NN
.  ||| S:370 E:372 ||| .
Some  ||| S:372 E:377 ||| DT
researchers  ||| S:377 E:389 ||| NNS
believe  ||| S:389 E:397 ||| VBP
that  ||| S:397 E:402 ||| IN
specific  ||| S:402 E:411 ||| JJ
chemical  ||| S:411 E:420 ||| NN
constituents  ||| S:420 E:433 ||| NNS
of  ||| S:433 E:436 ||| IN
St  ||| S:436 E:439 ||| NNP
John ||| S:439 E:443 ||| NNP
's  ||| S:443 E:446 ||| POS
wort  ||| S:446 E:451 ||| JJ
produce  ||| S:451 E:459 ||| NN
change  ||| S:459 E:466 ||| NN
in  ||| S:466 E:469 ||| IN
depression  ||| S:469 E:480 ||| NN
in  ||| S:480 E:483 ||| IN
a  ||| S:483 E:485 ||| DT
way  ||| S:485 E:489 ||| NN
similar  ||| S:489 E:497 ||| JJ
to  ||| S:497 E:500 ||| TO
that  ||| S:500 E:505 ||| DT
of  ||| S:505 E:508 ||| IN
antidepressant  ||| S:508 E:523 ||| JJ
medications ||| S:523 E:534 ||| NN
,  ||| S:534 E:536 ||| ,
yet  ||| S:536 E:540 ||| RB
this  ||| S:540 E:545 ||| DT
hypothesis  ||| S:545 E:556 ||| NN
is  ||| S:556 E:559 ||| VBZ
problematic ||| S:559 E:570 ||| JJ
.  ||| S:570 E:572 ||| .
In  ||| S:572 E:575 ||| IN
addition ||| S:575 E:583 ||| NN
,  ||| S:583 E:585 ||| ,
studies  ||| S:585 E:593 ||| NNS
that  ||| S:593 E:598 ||| WDT
support  ||| S:598 E:606 ||| VBP
the  ||| S:606 E:610 ||| DT
efficacy  ||| S:610 E:619 ||| NN
of  ||| S:619 E:622 ||| IN
St  ||| S:622 E:625 ||| NNP
John ||| S:625 E:629 ||| NNP
's  ||| S:629 E:632 ||| POS
wort  ||| S:632 E:637 ||| NN
in  ||| S:637 E:640 ||| IN
patients  ||| S:640 E:649 ||| NNS
with  ||| S:649 E:654 ||| IN
mild-to-moderate  ||| S:654 E:671 ||| JJ
depression  ||| S:671 E:682 ||| NN
have  ||| S:682 E:687 ||| VBP
limitations  ||| S:687 E:699 ||| NNS
that  ||| S:699 E:704 ||| WDT
may  ||| S:704 E:708 ||| MD
affect  ||| S:708 E:715 ||| VB
the  ||| S:715 E:719 ||| DT
accuracy  ||| S:719 E:728 ||| NN
of  ||| S:728 E:731 ||| IN
their  ||| S:731 E:737 ||| PRP$
conclusions ||| S:737 E:748 ||| NNS
.  ||| S:748 E:750 ||| .
Studies  ||| S:750 E:758 ||| NNS
measuring  ||| S:758 E:768 ||| VBG
the  ||| S:768 E:772 ||| DT
effect  ||| S:772 E:779 ||| NN
of  ||| S:779 E:782 ||| IN
St  ||| S:782 E:785 ||| NNP
John ||| S:785 E:789 ||| NNP
's  ||| S:789 E:792 ||| POS
wort  ||| S:792 E:797 ||| NN
in  ||| S:797 E:800 ||| IN
major  ||| S:800 E:806 ||| JJ
depression  ||| S:806 E:817 ||| NN
have  ||| S:817 E:822 ||| VBP
reported  ||| S:822 E:831 ||| VBN
conflicting  ||| S:831 E:843 ||| JJ
results  ||| S:843 E:851 ||| NNS
and  ||| S:851 E:855 ||| CC
need  ||| S:855 E:860 ||| VBP
to  ||| S:860 E:863 ||| TO
be  ||| S:863 E:866 ||| VB
reexamined ||| S:866 E:876 ||| NNS
.  ||| S:876 E:878 ||| .
Because  ||| S:878 E:886 ||| IN
St  ||| S:886 E:889 ||| NNP
John ||| S:889 E:893 ||| NNP
's  ||| S:893 E:896 ||| POS
wort  ||| S:896 E:901 ||| NN
is  ||| S:901 E:904 ||| VBZ
considered  ||| S:904 E:915 ||| VBN
by  ||| S:915 E:918 ||| IN
some  ||| S:918 E:923 ||| DT
to  ||| S:923 E:926 ||| TO
be  ||| S:926 E:929 ||| VB
an  ||| S:929 E:932 ||| DT
alternative  ||| S:932 E:944 ||| NN
to  ||| S:944 E:947 ||| TO
conventional  ||| S:947 E:960 ||| JJ
therapies ||| S:960 E:969 ||| NNS
,  ||| S:969 E:971 ||| ,
clinicians  ||| S:971 E:982 ||| NNS
need  ||| S:982 E:987 ||| VBP
to  ||| S:987 E:990 ||| TO
know  ||| S:990 E:995 ||| VB
whether  ||| S:995 E:1003 ||| IN
it  ||| S:1003 E:1006 ||| PRP
is  ||| S:1006 E:1009 ||| VBZ
an  ||| S:1009 E:1012 ||| DT
effective  ||| S:1012 E:1022 ||| JJ
and  ||| S:1022 E:1026 ||| CC
safe  ||| S:1026 E:1031 ||| JJ
treatment  ||| S:1031 E:1041 ||| NN
for  ||| S:1041 E:1045 ||| IN
different  ||| S:1045 E:1055 ||| JJ
levels  ||| S:1055 E:1062 ||| NNS
of  ||| S:1062 E:1065 ||| IN
severity  ||| S:1065 E:1074 ||| NN
of  ||| S:1074 E:1077 ||| IN
depression ||| S:1077 E:1087 ||| NN
.  ||| S:1087 E:1089 ||| .
Current  ||| S:1089 E:1097 ||| JJ
evidence  ||| S:1097 E:1106 ||| NN
does  ||| S:1106 E:1111 ||| VBZ
not  ||| S:1111 E:1115 ||| RB
support  ||| S:1115 E:1123 ||| VB
its  ||| S:1123 E:1127 ||| PRP$
use ||| S:1127 E:1130 ||| NN
,  ||| S:1130 E:1132 ||| ,
and ||| S:1132 E:1135 ||| CC
,  ||| S:1135 E:1137 ||| ,
because  ||| S:1137 E:1145 ||| IN
of  ||| S:1145 E:1148 ||| IN
potential  ||| S:1148 E:1158 ||| JJ
drug  ||| S:1158 E:1163 ||| NN
interactions ||| S:1163 E:1175 ||| NNS
,  ||| S:1175 E:1177 ||| ,
St  ||| S:1177 E:1180 ||| NNP
John ||| S:1180 E:1184 ||| NNP
's  ||| S:1184 E:1187 ||| POS
wort  ||| S:1187 E:1192 ||| NN
is  ||| S:1192 E:1195 ||| VBZ
not  ||| S:1195 E:1199 ||| RB
a  ||| S:1199 E:1201 ||| DT
benign  ||| S:1201 E:1208 ||| JJ
treatment ||| S:1208 E:1217 ||| NN
.  ||| S:1217 E:1219 ||| .
